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Myocardial Perfusion Imaging Versus Computed Tomography
Angiography–Derived Fractional Flow Reserve Testing in Stable
Patients With Intermediate-Range Coronary Lesions: Inﬂuence on
Downstream Diagnostic Workﬂows and Invasive Angiography
Findings
Bjarne L. Nørgaard, MD, PhD; Lars C. Gormsen, MD, PhD; Hans Erik Bøtker, MD, PhD; Erik Parner, MD, PhD; Lene H. Nielsen, MD, PhD;
Ole N. Mathiassen, MD, PhD; Erik L. Grove, MD, PhD; Kristian A. Øvrehus, MD, PhD; Sara Gaur, MD, PhD; Jonathon Leipsic, MD, PhD;
Kamilla Pedersen, BSc; Christian J. Terkelsen, MD, PhD; Evald H. Christiansen, MD, PhD; Anne Kaltoft, MD, PhD; Michael Mæng, MD, PhD;
Steen D. Kristensen, MD, PhD; Lars R. Krusell, MD; Jens F. Lassen, MD, PhD; Jesper M. Jensen, MD, PhD
Background-—Data on the clinical utility of coronary computed tomography angiography–derived fractional ﬂow reserve (FFRCT)
are sparse. In patients with intermediate (40–70%) coronary stenosis determined by coronary computed tomography angiography,
we investigated the association of replacing standard myocardial perfusion imaging with FFRCT testing with downstream utilization
of invasive coronary angiography (ICA) and the diagnostic yield of ICA (rate of no obstructive disease, and rate of revascularization).
Methods and Results-—This was a single-center observational study of symptomatic patients with suspected coronary artery
disease referred to coronary computed tomography angiography between 2013 and 2015. Patients were divided into 3 historical
groups based on the adjunctive functional testing approach: myocardial perfusion imaging (n=1332) or FFRCT “implementation”
(n=800) or “clinical use” (n=1391). Propensity score matching was used to estimate the average period effect on outcomes.
Patients in the FFRCT clinical use group versus the myocardial perfusion imaging group were older and had higher pretest
probability of obstructive disease. After adjusting for baseline risk characteristics, there was a reduction in downstream ICA
utilization (absolute risk difference: 4.2; 95% CI, 6.9 to 1.6; P=0.002). In patients referred to ICA, ﬁndings of no obstructive
coronary artery disease decreased (12.8%; 95% CI, 22.2 to 3.4; P=0.008) and rate of coronary revascularization increased
(14.1%; 95% CI, 3.3–24.9; P=0.01), as did availability of functional information for guidance of revascularization (27.8%; 95% CI,
11.3–44.4; P<0.001) after clinical adoption of FFRCT.
Conclusions-—Replacing adjunctive myocardial perfusion imaging with FFRCT testing for functional assessment of intermediate
stenosis determined by coronary computed tomography angiography in stable coronary artery disease was associated with less
ICA utilization, and a higher ICA diagnostic yield. The ﬁndings in this observational study needs conﬁrmation in prospective,
randomized trials. ( J Am Heart Assoc. 2017;6:e005587. DOI: 10.1161/JAHA.117.005587.)
Key Words: computed tomography angiography • coronary artery disease • imaging • positron emission tomography
C oronary computed tomography angiography (CTA) isincreasingly used as an alternative to frontline functional
testing in patients with suspected stable coronary artery
disease (CAD). Coronary CTA, however, tends to overestimate
stenosis severity, and the correlation to downstream myocar-
dial ischemia is poor.1 Consequently, guidelines recommend
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that ischemia testing should be performed before referral to
invasive coronary angiography (ICA) when coronary CTA
shows signiﬁcant CAD.2
Recent advances in individual image-based modeling and
computational ﬂuid dynamics allow for estimation of
coronary blood ﬂow and pressure from coronary CTA
images.3 Based on these techniques, noninvasive fractional
ﬂow reserve (FFR) can be computed.3–6 In studies including
patients with known or suspected stable CAD and blinded
comparison to FFR, coronary CTA-derived FFR (FFRCT) has
shown high diagnostic performance.4–6 Recently, it was
demonstrated in stable patients referred to ICA that initial
FFRCT assessment reduced the downstream use of ICA
procedures, the rate of ICA showing no obstructive CAD,
and overall costs.7 Although results are promising, the real-
world clinical utility of FFRCT is not known. The purpose of
this observational study was to assess replacement of an
adjunctive diagnostic strategy of conventional myocardial
perfusion imaging (MPI) with FFRCT in stable patients
with intermediate-range coronary stenosis determined by
coronary CTA on (1) the rate of downstream ICA utilization
and (2) the diagnostic yield of ICA, deﬁned as proportion
of ICA showing no obstructive CAD, and the rate of
revascularization.
Methods
We conducted a single-center observational all-comer study of
symptomatic patients with suspected CAD undergoing coro-
nary CTA at Aarhus University Hospital in Denmark between
May 1, 2013, and December 31, 2015. At our institution,
coronary CTA testing has been the preferred initial diagnostic
modality since 2009 for patients with new-onset chest pain
without known CAD and low-intermediate pretest probability
of CAD. Noninvasive ischemia testing (using exercise electro-
cardiography) was performed before the time of coronary CTA
acquisition only in patients referred from private cardiolgist
practices. In patients with intermediate-range (30–70%)
coronary stenosis, adjunctive functional testing is recom-
mended before decision making about referral to ICA. Until
2014, adjunctive functional testing at this institution was
performed by conventional MPI. Based on local pilot experi-
ences together with published reports on the diagnostic
performance of FFRCT testing
4–6 and potential improvements
in clinical workﬂows, we decided in 2014 to replace MPI with
FFRCT for functional assessment of CAD determined by
coronary CTA. At our institution, frontline MPI of patients
with new-onset chest pain without known CAD is recom-
mended only for those with contraindications to coronary
CTA.8 Patients were divided into 3 historical groups based on
the adjunctive functional testing approach: (1) rest–stress
rubidium-82 positron emission tomography (Rb-PET) or ses-
tamibi SPECT (single-photon emission CT; May 2013 to April
2014, “MPI era”), (2) FFRCT as an alternative to MPI
assessment (May 2014 to December 2014, during which
our institution and physicians became familiar with the use of
the FFRCT technology), and (3) FFRCT testing fully incorporated
into clinical practice (January 2015 to December 2015). Local
recommendations on diagnostic workﬂows in the MPI era and
during both periods of FFRCT use (FFRCT era) are described in
Table 1. Demographic and clinical characteristics were
obtained from patient ﬁles and registries.9 The study was
approved by the Danish Data Protection Agency (1-16-02-229-16)
with a waiver of individual informed consent from the regional
ethics committee.
Coronary CTA
Coronary CTA was performed using a dual-source scanner, as
described previously.8 In brief, image acquisition was per-
formed in accordance with best practice guidelines.10 Con-
traindications to coronary CTA were known CAD, scenarios in
which a nondiagnostic test result could appear with high
probability (eg, patients with arrhythmia or obesity, high
Agatston score), severe renal insufﬁciency, pregnancy, or
allergy to contrast. The decision to perform coronary CTA in
patients with a high Agatston score was based on symptom
Clinical Perspectives
What Is New?
• This single-center, real-world-practice, observational study
used a strategy of replacing adjunctive rubidium-82 positron
emission tomography with coronary computed tomography
angiography–derived fractional ﬂow reserve testing for
functional assessment of intermediate stenosis, determined
by coronary computed tomography angiography, in patients
with stable coronary artery disease. This approach was
associated with a reduction in the number of patients who
had to return for a second noninvasive test, less down-
stream invasive coronary angiography utilization, a reduc-
tion in the rate of ﬁnding no obstructive coronary artery
disease at invasive coronary angiography, an increase in
availability of lesion-speciﬁc functional information for
guidance of coronary interventions, and a higher rate of
revascularization with no sacriﬁce of short-term adverse
clinical outcomes.
What Are the Clinical Implications?
• Large-scale multicenter prospective studies are needed to
delineate the relative diagnostic yield, safety, and costs of
adjunctive coronary computed tomography angiography–
derived fractional ﬂow reserve versus myocardial perfusion
imaging testing in stable patients undergoing coronary
computed tomography angiography.
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severity and the probability of good image quality, taking into
account issues related to, for example, patient cooperation,
weight, andheart rate, at thediscretionof the treating physician.
Oral and/or intravenous b-blockers or oral ivabradine were
administered if necessary, targeting a heart rate <60 beats per
minute, and patients received sublingual spray nitroglycerin
0.8 mg <5 minutes before the scan. An initial nonenhanced
scan was performed using high-pitch spiral acquisition, from
which the Agatston score was assessed. Coronary CTA was
performed using prospective electrocardiographic triggering.
Images were reconstructed using ﬁltered back projection.
Scans were assessed using axial images and multiplanar
reconstructions by experienced cardiologists with a mean of 6
years of experience interpreting coronaryCTA.Vessel segments
≥2 mm were evaluated for lumen narrowing. For guidance of
downstream patient management, the CT-reading cardiologists
grouped patients into 1 of 3 risk categories8 (Table 1).
Myocardial Perfusion Imaging
Rb-PET is our preferred MPI test. Rb-PET scans (rest and
stress) using bolus injections of 1110 MBq rubidium-82 were
performed on a GE Discovery 690 PET/CT system (GE
Healthcare). International standard adenosine infusion
(0.140 mg/kg per minute) and reconstruction protocols
(static and dynamic images) were applied.11 Rb-PET myocar-
dial perfusion images were analyzed qualitatively using
differences in relative counts between rest and stress.12
Any signiﬁcant visual regional tracer redistribution between
the rest and stress studies was interpreted as an inducible
perfusion defect. Finally, absolute ﬂow values calculated
based on data from the dynamic acquisition data were
reported in cases of balanced 3-vessel disease or diffuse
disease. In these cases, global myocardial blood ﬂow <2 mL/
g per minute was reported to be abnormally low. A positive
Rb-PET result was present in the event of visual regional
tracer redistribution between the rest and stress studies or
myocardial blood ﬂow <2 mL/g per minute. In the event of
contraindications to adenosine, exercise sestamibi SPECT was
performed.13 Local recommendations regarding the clinical
consequence of test results are shown in Table 1.
Coronary CTA-Derived FFR
Standard coronary CTA data sets were transmitted for
analysis.6 The scientiﬁc basis of FFRCT computation has been
described previously.3 FFRCT values in the major epicardial
arteries (left main, left anterior descending, left circumﬂex,
and right coronary; including side branches) ≥2 mm in
diameter were registered. Between May 2014 and April
2015, we recommended that ICA should be performed in
patients with FFRCT ≤0.80; subsequently, we lowered the
threshold to 0.75 for referral to ICA.8 This decision was made
because we observed substantial discordance in our clinical
practice between measured FFR and FFRCT in patients with
lowest FFRct values between 0.76 and 0.80.8 In the latter
period, in patients with FFRCT between 0.75 and 0.80, a
strategy of optimal medical treatment was recommended
together with ambulatory follow-up after 3 months, with
referral to ICA only in the event of ongoing chest pain.8 Local
recommendations for downstream patient management
based on FFRCT results are shown in Table 1.
ICA and FFR
ICA and FFR were performed according to standard practice
by experienced invasive cardiologists. All information relevant
for patient management, including the MPI and FFRCT results,
were available for decision making, and measurement of FFR
and coronary revascularization were performed at the discre-
tion of the treating physicians. Patients without obstructive
CAD (no coronary lesions ≥50% lumen reduction) were
registered. For this study, the degree of angiographic vessel
stenosis was determined by experienced interventionalists
Table 1. Local Recommendations Regarding Downstream
Diagnostic Work-up in Patients Following Coronary CTA, MPI,
and FFRCT Testing Between May 1, 2013, and December 31,
2015
Test Outcome
Diagnostic
Recommendations*
Frontline coronary CTA
Diagnostic conclusive High risk† ICA
Intermediate risk‡ Functional testing
Low risk§ OMT§
Diagnostic inconclusive  OMTk, MPI or ICA
Functional testing
MPI (May 2013
to April 2014)
Positive or equivocal ICA
Negative OMTk
FFRCT (May 2014 to
December 2015)
Positive¶ ICA
Negative¶ OMTk
Inconclusive MPI or ICA
CTA indicates computed tomography angiography; FFRCT indicates coronary computed
tomography angiography–derived fractional ﬂow reserve; ICA, invasive coronary
angiography; MPI, myocardial perfusion imaging; OMT, optimal medical treatment
without additional testing.
*Other factors than test results (eg, symptom severity, patient preference) may have
inﬂuenced decisions on downstream patient management.
†Patients with left main, 3-vessel disease and/or high-grade proximal left anterior
descending artery stenosis.
‡Patients with ≥1 intermediate coronary stenosis (lumen reduction 30–70%).
§Patients without coronary disease or with maximum coronary stenosis <30%.
kIf disease was present, statin, aspirin, and antianginal medication were generally
recommended.
¶We recommended ICA to be performed in patients with FFRCT ≤0.80 between May 2014
and April 2015, after which the FFRCT threshold for referral to ICA was adjusted to 0.75.
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blinded to other patient information and the results of
preceding noninvasive tests (including MPI and FFRCT). FFR
measurements were performed using the Verrata (Volcano
Therapeutics) or Aeris (St. Jude Medical) pressure wire.
Patient Follow-up
Rates of follow-up in the 3 time periods of ICA, FFR, and
coronary revascularization (percutaneous coronary interven-
tion or coronary bypass grafting) within 3 months from the
time of coronary CTA were obtained from patient ﬁles and
registries.9 For patients with FFRCT ≤0.80 for whom a strategy
of optimal medical treatment with subsequent ambulatory
follow-up was initiated (Table 1), those diagnostic procedures
performed within 3 months after the ambulatory visit were
registered. All-cause death occurring within 6 months from
date of the CT investigation was ascertained from the Danish
Civil Registration system, which maintains complete data on
mortality.14
Radiation Exposure
Radiation exposure, including all diagnostic tests, are reported
in millisieverts using the formula mSv=(dose length product)
90.014 for coronary CTA, and with conversion factors of
0.18 mSv/(Gycm2) for ICA15 and 0.00126 MBq for MPI.16
Statistical Analysis
Categorical data are presented as numbers and proportions,
and continuous data are presented as meanSD, as appro-
priate. The Fisher exact test was used to compare categorical
data, the t test was used for comparison of means, and the
bootstrap procedure was used to compare means for
nonnormally distributed data. Propensity score matching
was used to adjust for differences in baseline patient
characteristics between time periods.17 Propensity score
matching was chosen rather than regression analysis because
of the limited number of events. The average period effect on
outcomes was quantiﬁed as a risk difference for the second
and third periods (test periods) compared with the ﬁrst period
(reference period). The propensity score was computed using
a logistic regression model including age as a second-order
polynomial (to account for a possible nonlinear effect of age),
sex, symptoms (nonanginal chest pain, atypical angina, or
typical angina), and Agatston score group (0, 1–100, 101–
400, >400). In subanalyses of patients with ICA and/or
coronary revascularization, propensity scoring was based only
on age and symptoms to account for the smaller sample size.
The average period effect was computed by taking the
average of the difference between the observed and matched
outcomes for each participant. Overlap in distribution of
baseline risk factors between time periods was large enough
to allow a propensity score matching strategy to adjust for
these differences. We performed an informal power calcula-
tion by considering the comparison of 2 proportions of size
(10% and 15%) in samples of 1300 patients, and found that
such a comparison would have a power of 97% in an
unadjusted analysis. All 95% conﬁdence intervals (CIs) and P
values were computed taking into account both the uncer-
tainty of the estimated propensity score and matching with
replacement. The distributions of risk factors were compared
between time periods before and after matching. A subanal-
ysis comparing outcomes in the MPI and FFRCT eras was
performed. Statistical analyses were performed using Stata
version 14.1 (StataCorp).
Results
The study cohort comprised 3523 consecutive patients.
Baseline characteristics of study patients are shown in
Table 2. Coronary CTA acquisition characteristics, information
on radiation exposure, and Agatston scores are shown in
Table 3. Radiation dose associated with coronary CTA
increased from 2.9 mSv in the MPI era to 3.4 mSv in the
FFRCT era (P<0.001).
Figure 1 displays the diagnostic ﬂow of patients in the 3
time periods. The coronary CTA result was inconclusive in 202
patients (6%). Noninvasive functional testing was performed in
711 patients (20%) with intermediate-range coronary lesions.
Of 347 MPI investigations, 95% were Rb-PET and 5% were
SPECT. The MPI result was positive in 45 patients (13%),
negative in 292 (84%), and in equivocal in 10 (3%). Over the
entire study period, the mean time between referral to MPI
and availability of the test result was 33 days (range: 8–59
days). Of 364 FFRCT assessments, FFRCT was >0.80 in all
vessels in 215 patients (59%) and ≤0.80 and ≤0.75 in at least
1 vessel in 133 (37%) and 77 (21%) patients, respectively. For
16 patients (4.3%), FFRCT could not be computed because of
motion, misalignment, low contrast, and/or calcium blooming
(n=12), missing myocardium or lack of CT diastole phase
(n=4). The FFRCT result was available for 96% of the patients
<24 hours and in 100% <48 hours after the coronary CTA
examination.
Temporal Changes in Diagnostic Workﬂows,
Findings of No Obstructive CAD,
Revascularizations, and Clinical Outcomes
The proportion of inconclusive coronary CTA investigations
decreased from 7.0% to 6.1% and 4.3% over the 3 time
periods (P<0.001). The proportion of patients with high-risk-
anatomy ﬁndings determined by coronary CTA referred
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directly to ICA without functional testing were 8.2%, 5.5%,
and 6.1% in periods 1, 2, and 3, respectively (P<0.001).
Temporal changes in downstream utilization of MPI, FFRCT,
and FFR are shown in Figure 2. The proportion of patients
who had to come back for a second noninvasive test after
coronary CTA declined after FFRCT adoption, from 17.3%
Table 2. Patient Characteristics
Characteristic
Period 1
(n=1332)
Period 2
(n=800)
Period 3
(n=1391)
Periods 1 vs 2
(P Value)
Periods 1 vs 3
(P Value)
Mean (SD) age, y 56 (11) 57 (11) 58 (11) 0.05 0.001
Male sex 629 (47) 371 (46) 655 (47) 0.7 1.0
Diabetes mellitus 105 (8) 57 (7) 118 (9) 0.6 0.6
Hypertension 482 (36) 267 (33) 497 (36) 0.15 0.8
Hyperlipidemia 411 (31) 240 (30) 425 (31) 0.7 1.0
Current smoker 303 (23) 176 (22) 303 (22) 0.7 0.6
Family history of CAD 669 (50) 382 (48) 635 (48) 0.24 0.05
Symptoms
Typical angina 146 (11) 99 (12) 226 (16) <0.001 <0.001
Atypical angina 835 (63) 606 (76) 908 (66)
Nonanginal chest pain 347 (26) 93 (12) 249 (18)
Mean (SD) updated Diamond-
Forrester risk score, %
32 (19) 35 (18) 35 (20) <0.001 <0.001
Intermediate (20–80%) pretest risk 871 (65) 585 (73) 979 (70) <0.001 <0.001
Noninvasive ischemia testing performed
before coronary CTA*
146 (11) 96 (12) 149 (11) 0.5 1.00
Mean (SD) body mass index, kg/m2 26 (4) 26 (5) 26 (4) 0.8 0.8
Mean (SD) serum creatinine, lmol/L 75 (22) 75 (16) 76 (28) 0.9 0.4
Values are mean (SD), or number (proportion). CAD indicates coronary artery disease; CTA, computed tomography angiography.
*Pre-coronary CTA noninvasive ischemia testing (using exercise electrocardiography) was performed in patients referred from private cardiologist practices. Time period 1, May 2013 to
April 2014; period 2, May 2014 to December 2014; period 3, January 2015 to December 2015.
Table 3. Coronary CTA Acquisition Characteristics, Radiation Exposure, and Agatston Scores
Characteristic Period 1 (n=1332) Period 2 (n=800) Period 3 (n=1391) Periods 1 vs 2 (P Value) Periods 1 vs 3 (P Value)
Mean (SD) heart rate, bpm 59 (10) 58 (10) 59 (10) 0.03 0.81
Sinus rhythm 1259 (95) 761 (95) 1340 (96) 0.62 0.03
Prescan administration of nitrates 1272 (95) 770 (96) 1348 (97) 0.40 0.05
Prescan administration of beta-blockers 1146 (86) 675 (84) 1154 (83) 0.29 0.03
Prospective acquisition 1276 (96) 776 (97) 1363 (98) 0.13 <0.001
Retrospective acquisition 16 (1) 8 (1) 14 (1) 0.67 0.63
High-pitch spiral acquisition 40 (3) 16 (2) 14 (1) 0.19 <0.001
Mean (SD) diagnostic radiation exposure, mSv
Cumulative radiation exposure* 4.0 (2.2) 3.8 (2.0) 4.1 (2.1) 0.09 0.62
Coronary CTA† 2.9 (1.4) 3.0 (1.5) 3.4 (1.7) 0.10 <0.001
Mean (SD) Agatston score 98 (316) 111 (337) 143 (496) 0.43 0.001
Agatston >400 80 (6) 57 (7) 113 (8) 0.23 0.02
Values are mean (SD) or number (proportion). CTA indicates computed tomography angiography; MPI, myocardial perfusion imaging.
*Including diagnostic coronary CTA, index and downstream MPI, and invasive coronary angiography. For MPI, both rest and stress tests were included in the radiation estimate. For
coronary CTA, both the scout, noncontrast and contrast scans were included in the estimate.
†Coronary CTA investigations only.
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Figure 1. Flow of study patients. The functional signiﬁcance of intermediate-range
lesions (30–70%) determined by coronary CTA was assessed by MPI (period 1) or FFRCT
(periods 2 and 3). Numbers refer to the number of patients in each group. Numbers in
parentheses refer to number of patients having fractional ﬂow reserve (95%) or
instantaneous wave-free ratio (5%) performed. CTA indicates computed tomography
angiography; FFRCT indicates coronary computed tomography angiography–derived
fractional ﬂow reserve; ICA, invasive coronary angiography; MPI, myocardial perfusion
imaging; OMT, optimal medical treatment without additional testing.
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(231/1332) in period 1 to 4.1% (57/1391) in period 3
(P<0.001). Rates of ICA utilization, ﬁndings of no obstruc-
tive CAD, rates of revascularization, and proportions of
patients undergoing revascularization with available func-
tional information are shown in Table 4. Unadjusted risk
differences in rates of ICA, ﬁndings of no obstructive
disease, availability of functional information, and revascu-
larization between the MPI and FFRCT eras are shown in
Figure 3. The rate of patients for whom functional infor-
mation (MPI, FFRCT, and/or FFR) was available for guiding
revascularization was higher in period 3 (70%) than in
period 1 (35%; Figure S1). In 18 patients with FFRCT ranging
between 0.75 and 0.80, optimal medical treatment was
initiated with 3 months of ambulatory follow-up (Table 1).
Of these patients, 22% were referred to ICA after the
planned ambulatory visit. Eight patients (0.23%) died during
6-month follow-up: 3 (0.23%) in period 1, 2 (0.25%) in
period 2, and 3 (0.22%) in period 3. In these patients, the
coronary CTA result was normal (n=4), showed CAD
requiring no additional testing (n=2), or showed high-risk
CAD leading to direct ICA referral (n=2).
Adjusted Analyses
Following propensity score match analysis, comparisons of
periods 1 and 3 showed decreases in the use of ICA
(absolute risk difference: 4.2; 95% CI, 6.9 to 1.6;
P=0.002) and in the rate of ﬁnding no obstructive CAD
(absolute risk difference: 12.8%; 95% CI, 22.2 to 3.4;
P=0.008; Figure 4). Moreover, in patients who underwent
ICA, the rate of revascularization increased (14.1%; 95% CI,
3.3–24.9; P=0.01), as did availability of information regard-
ing lesion-speciﬁc ischemia for guiding therapeutic deci-
sions (27.8%; 95% CI, 11.3–44.4; P<0.001) after clinical
adoption of FFRCT.
Figure 2. Temporal changes in downstream utilization of functional tests. *Instantaneous wave-
free ratio was performed in 5% of the patients. FFR indicates fractional ﬂow reserve; FFRCT,
coronary computed tomography angiography–derived fractional ﬂow reserve; MPI, myocardial
perfusion imaging.
Table 4. Rates of Downstream ICA, Finding of No Obstructive
CAD, Coronary Revascularization, and Procedural Functional
Guidance
Group Period 1 Period 2 Period 3
All patients, n 1332 800 1391
ICA 172 (12.9) 107 (13.4) 190 (13.7)
No obstructive CAD 52 (3.9) 32 (4.0) 32 (2.3)
Coronary revascularization 72 (5.4) 47 (5.9) 102 (7.3)
≥1 functional test* 268 (20.1) 204 (25.5) 321 (23.1)
ICA, n 172 107 190
No obstructive CAD 52 (30.2) 32 (29.9) 32 (16.8)
Coronary revascularization 72 (41.9) 47 (43.9) 102 (53.7)
≥1 functional test* 61 (35.5) 63 (58.9) 110 (57.9)
Coronary revascularization, n 72 47 102
≥1 functional test* 23 (31.9) 26 (55.3) 61 (59.8)
Values are numbers (proportions). CAD indicates coronary artery disease; ICA, invasive
coronary angiography.
*Myocardial perfusion imaging, coronary computed tomography angiography–derived
fractional ﬂow reserve, and/or fractional ﬂow reserve. Time period 1, May 2013 to April
2014; period 2, May 2014 to December 2014; period 3, January 2015 to December
2015.
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Discussion
In this single-center observational study of symptomatic patients
with suspected CAD undergoing frontline coronary CTA testing,
a change in functional testing strategy from standard MPI to
FFRCT in patients with intermediate-range coronary lesions did
not affect overall downstream ICA utilization. However, following
adjustment for differences in baseline risk variables, adoption of
adjunctive FFRCT testing was associated with a reduction in
downstream use of ICA. Moreover, after adoption of FFRCT, we
observed a 75% reduction in patients who had to return for a
second noninvasive test. Finally, the introduction of FFRCT was
associated with a reduction in the rate of ﬁnding no obstructive
CAD at ICA, a higher rate of revascularization, and an increase in
availability of lesion-speciﬁc functional information for guidance
of coronary interventions.
Compared with MPI, the strength of coronary CTA is the
ability to accurately exclude, detect, and localize CAD. In the
recent PROMISE and SCOT-HEART trials, frontline coronary
CTA compared with noninvasive functional assessment in
patients with stable CAD enhanced diagnostic certainty and
favorably inﬂuenced the diagnostic workﬂow and therapeutic
plans.18,19 Coronary CTA, however, overestimates the severity
of lesions and cannot reliably determine their functional
signiﬁcance.1 This gap in noninvasive diagnostic testing may
be addressed by combining anatomic and physiologic data.20
In accord with the present ﬁndings, the prognosis in
contemporary patients undergoing noninvasive testing for
suspected CAD is favorable, with an annual risk of nonfatal
myocardial infarction or all-cause death of 1%.7,18,19 Con-
sequently, demonstrating a beneﬁt for clinical outcome with a
new diagnostic test for stable CAD is complex. To the best of
our knowledge, no previous study has assessed the potential
impact of frontline coronary CTA testing in combination with
different functional test strategies on downstream diagnostic
workﬂows and the quality of information for guiding care. In
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Figure 3. Unadjusted risk differences in rates of ICA, availability
of functional information, ﬁndings of no obstructive disease, and
revascularization in all patients, patients undergoing ICA, and
patients undergoing revascularization. A, Time period 1 (May 2013
to April 2014) vs periods 2 and 3 (May 2014 to December 2015). B,
Time periods 1 vs 3 (January 2015 to December 2015). CAD
indicates coronary artery disease; CI, conﬁdence interval; ICA,
invasive coronary angiography.
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Figure 4. Adjusted risk differences in rates of ICA, availability of
functional information, ﬁndings of no obstructive disease, and
revascularization in all patients, patients undergoing ICA, and
patients undergoing revascularization. A, Time period 1 (May 2013
to April 2014) vs periods 2 and 3 (May 2014 to December 2015);
(B) Time periods 1 vs 3 (January 2015 to December 2015). CAD
indicates coronary artery disease; CI, conﬁdence interval; ICA,
invasive coronary angiography.
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the recent PLATFORM study of patients with suspected stable
CAD and planned ICA, FFRCT testing was associated with a
safe reduction in downstream ICA utilization, a reduced rate of
ICA showing no obstructive CAD, and an increase in the
availability of functional information to guide therapeutic
decision making.7 The present study adds to these ﬁndings by
demonstrating comparable results in a real-world clinical
setting of stable patients with chest pain in whom coronary
CTA testing was performed according to guidelines2 and in
whom the overall ICA referral rate was low (13%).
Because MPI or FFRCT testing strategies in this report were
used almost exclusively as gatekeepers for ICA in patients
with intermediate-range stenosis, the frequency of inappro-
priate referrals to ICA may be considered as an indirect metric
of false-positive rates. In this study, the rate of ﬁnding
no obstructive CAD at ICA declined by almost 50% following
clinical adoption of FFRCT. These ﬁndings are in accordance
with the PLATFORM study, which showed an 83% reduction in
ﬁndings of no obstructive CAD at ICA when using FFRCT
testing after coronary CTA rather than direct referral to ICA.7
Of note, the proportion of patients with no obstructive CAD at
ICA in this study (17–30%) was lower than previously reported
(50–60%).21 This ﬁnding most likely reﬂects the rigor-
ous anatomical–functional assessment in the majority of
patients before referral to ICA at this institution. The higher
diagnostic yield in the FFRCT era versus the MPI era in this
study is supported by observations that, even after adjustment
for differences in baseline characteristics between time
periods, there was a 14% absolute increase in the revascular-
ization rate together with a 28% increase in availability of lesion-
speciﬁc functional information at the time of revascularization.
Guidelines recommend functional information for decision
making regarding revascularization in patients with interme-
diate-range coronary lesions.2 In contemporary clinical prac-
tice, however, less than two-thirds of patients undergo
noninvasive ischemia testing before ICA.21,22 FFR is a robust
tool for the adjudication of the hemodynamic signiﬁcance of a
stenosis; however, FFR interrogation carries risk of complica-
tions, it cannot be performed in all vessels (eg, occluded
vessels, severe tortuosity, and/or calciﬁcation), and it is
costly. Consequently, the adoption of FFR in clinical practice
is limited.23,24 In this study, from the MPI era to the FFRCT era,
we observed doubling in the rate of patients with functional
information available for decision making on downstream
diagnostic and therapeutic management. Surprisingly, during
the FFRCT implementation phase, there was a notable
increase in the use of FFR. This ﬁnding most likely reﬂects
a generally higher recognition of the need for functional
information to guide patient care over time, together with an
initial FFRCT diagnostic uncertainty among the treating
physicians, prompting “conﬁrmatory” FFR interrogation in
many vessels.8 The latter is supported by the observation that
following FFRCT adoption, FFR measurements decreased in
parallel with an increased reliance on FFRCT for revascular-
ization guidance.
We observed that the proportion of patients being referred
directly to ICA without functional testing declined during the
study period. This ﬁnding may reﬂect an increased focus on
coronary CTA image quality during the clinical adoption of
FFRCT.
8 Moreover, it may be speculated that in challenging
cases with high-risk anatomy, FFRCT testing encourages
higher observer conﬁdence in test results compared with
standard practice. This is supported by the high and superior
diagnostic performance of FFRCT compared with coronary CTA
interpretation in patients with high levels of coronary
calciﬁcation25 and by our observation of increasing Agatston
scores during the study period.
There has been much focus on the radiation dose
associated with coronary CTA testing.14 In this study reﬂect-
ing contemporary practice, mean radiation associated with
coronary CTA testing was relatively low. Despite the reduction
in the rate of MPI testing during the study period, we could
not demonstrate a decline in the overall mean radiation dose
(4 mSv) following the introduction of FFRCT testing. This
reﬂects a modest increase in radiation dose associated with
coronary CTA testing over time (2.9–3.4 mSv). The latter
ﬁnding presumably relates to higher focus on image quality in
parallel with the introduction of FFRCT. Accordingly, we
observed a reduction in the use of low-radiation, high-pitch
spiral acquisition scans over time. Moreover, an increase in
prospective CTA acquisition padding duration over time may
have occurred (data not available).
In the present study, only patients with new-onset chest
pain were included. It should be acknowledged that the
diagnostic performance of FFRCT in patients with known CAD
(eg, prior coronary intervention, previous myocardial infarc-
tion) is not known. At present, the use of FFRCT in patients
with suspected or known acute coronary syndromes cannot
be recommended.26 Furthermore, the diagnostic performance
of FFRCT in patients with documented microvascular disease
has not been investigated. It cannot be excluded that
discrepancies between FFRCT and invasive FFR may be due
to microvascular disease. In these circumstances, MPI may
provide additional prognostic information. Currently, FFRCT
requires offsite computer processing with a 24-hour response
time. Reduced order models for FFRCT computation may allow
for onsite FFRCT assessment in the future.
27 However, further
investigation in prospective multicenter trials are needed to
determine the diagnostic performance of these techniques.28
Of note, not all patients are suitable for coronary CTA testing
(eg, because of contrast allergy, renal impairment, obesity,
arrhythmia, and/or high coronary calciﬁcation). Because
FFRCT is derived from coronary CTA imaging data, CT artifacts
may inherently impair the diagnostic utility of FFRCT.
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Accordingly, in the present study, coronary CTA was deemed
inconclusive in 5% of cases during the FFRCT testing era. In
contrast to coronary CTA (and FFRCT), MPI is a well-validated
modality for assessment of symptomatic patients with known
CAD (eg, previous coronary intervention or myocardial
infarction). Accordingly, the recently updated UK NICE
(National Institute for Health and Care Excellence) guidelines
on the management of stable patients with chest pain
recommend frontline coronary CTA testing in patients without
known CAD and MPI in patients with known CAD.29 Of note,
US guidelines do not recommend frontline coronary CTA
testing in patients with chest pain.
Study Limitations
This was a single-center, nonrandomized, observational study.
Although we adjusted for factors that were expected to
inﬂuence outcomes, residual confounding may remain. This
study, however, includes a large all-comer consecutive
symptomatic cohort with limited exclusion criteria, relevant
for frontline coronary CTA testing, and thus is representative
of patients encountered in clinical practice. General changes
in time trends in relation to referrals for ICA, decision making
on coronary revascularization, and availability of functional
information may have inﬂuenced outcomes. However, data
were collected over a relatively narrow time span, and there
were no signiﬁcant changes in medical guidelines on the
management of stable CAD throughout the study period.2
Moreover, there was no change in CT technology or CT
interpretation experience (data not shown) during the study
course. In Denmark, we have universal tax-supported health
care that guarantees unfettered access to the hospital, to
general practitioners, and to prescribed medications, thus, no
healthcare service is “reimbursement driven.” Therefore,
major changes in management of patients unrelated to the
adjunctive functional testing strategy in this study seem
unlikely. In this study, MPI was performed using Rb-PET, which
is less widely applied in clinical practice than SPECT30;
therefore, the ﬁndings in this study may not be generalizable
to many sites. Rb-PET, however, is associated with less
radiation, more expedited examination time, and higher
diagnostic performance compared with SPECT.30 It is possible
that lack of standardized core laboratory analysis of MPI data
in this study may have biased the study outcome in favor of
FFRCT. Indeed, central processing of FFRCT allows for uniform
CT image quality control, processing of image data, accumu-
lation of data and machine learning with continuous reﬁne-
ments in technology and physiologic modeling, and
improvement in diagnostic performance6; however, the diag-
nostic strategies in this study represent real-world practice.
The change during period 3 in the FFRCT threshold for referral
to ICA from 0.80 to 0.75 involved a limited number of patients
and thus had no signiﬁcant impact on study outcomes (data
not shown); however, safety and impact on downstream
testing and treatment following introduction of the adjusted
FFRCT interpretation strategy needs delineation in future
studies. This study is further limited by the lack of information
on downstream angina or changes in medication. Information
on coronary stenosis severity would have provided valuable
information. Moreover, the follow-up period was short, leaving
questions related to costs and long-term adverse clinical
outcomes unanswered.
Conclusions
Replacing adjunctive MPI with FFRCT testing for functional
assessment of intermediate stenosis determined by coronary
CTA in patients with stable CAD was associated with less ICA
utilization and higher ICA diagnostic yield. Further testing in
randomized settings with longer follow-up is needed to assess
the relative diagnostic yield, safety, and costs of adjunctive
MPI versus FFRCT testing in stable patients undergoing
coronary CTA.
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Figure S1. Temporal Changes in Rates of Patients in Whom Functional Information was 
Available for Guidance of Revascularization 
 
*Instantaneous wave-free ratio was performed in 7% of the patients. FFR, fractional flow reserve; 
FFRCT, coronary computed tomography angiography derived fractional flow reserve; ICA, invasive 
coronary angiography; MPI, myocardial perfusion imaging.  
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